» Articles » PMID: 26587058

A New Compound Heterozygosis for Inactivating Mutations in the Glucokinase Gene As Cause of Permanent Neonatal Diabetes Mellitus (PNDM) in Double-first Cousins

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2015 Nov 21
PMID 26587058
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Permanent neonatal diabetes mellitus (PNDM) is a rare disorder, characterized by uncontrolled hyperglycemia diagnosed during the first 6 months of life. In general, PNDM has a genetic origin and most frequently it results from heterozygous mutations in KCNJ11, INS and ABCC8 genes. Homozygous or compound heterozygous inactivating mutations in GCK gene as cause of PNDM are rare. In contrast, heterozygosis for GCK inactivating mutations is frequent and results in the maturity-onset diabetes of young (MODY), manifested by a mild fasting hyperglycemia usually detected later in life. Therefore, as an autosomal recessive disorder, GCK-PNDM should be considered in families with history of glucose intolerance or MODY in first relatives, especially when consanguinity is suspected.

Results: Here we describe two patients born from non-consanguineous parents within a family. They presented low birth weight with persistent hyperglycemia during the first month of life. Molecular analyses for KCNJ11, INS, ABCC8 did not show any mutation. GCK gene sequencing, however, revealed that both patients were compound heterozygous for two missense combined in a novel GCK-PNDM genotype. The p.Asn254His and p.Arg447Gly mutations had been inherited from their mothers and fathers, respectively, as their mothers are sisters and their fathers are brothers. Parents had been later diagnosed as having GCK-MODY.

Conclusions: Mutations' in silico analysis was carried out to elucidate the role of the amino acid changes on the enzyme structure. Both p.Asn254His and p.Arg447Gly mutations appeared to be quite damaging. This is the first report of GCK-PNDM in a Brazilian family.

Citing Articles

ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents.

Greeley S, Polak M, Njolstad P, Barbetti F, Williams R, Castano L Pediatr Diabetes. 2022; 23(8):1188-1211.

PMID: 36537518 PMC: 10107883. DOI: 10.1111/pedi.13426.


A Novel Large Genomic Rearrangement in a Patient with MODY-2 Detected by Clinical Exome Sequencing.

Concolino P, Tartaglione L, De Paolis E, Carrozza C, Urbani A, Minucci A Genes (Basel). 2022; 13(11).

PMID: 36421779 PMC: 9690203. DOI: 10.3390/genes13112104.


Variable presentations of gene mutation in a family.

Oza C, Karguppikar M, Khadilkar V, Khadilkar A BMJ Case Rep. 2022; 15(2).

PMID: 35228227 PMC: 8886375. DOI: 10.1136/bcr-2021-246699.


Do second generation sequencing techniques identify documented genetic markers for neonatal diabetes mellitus?.

Ali Khan I Heliyon. 2021; 7(9):e07903.

PMID: 34584998 PMC: 8455689. DOI: 10.1016/j.heliyon.2021.e07903.


Monogenic diabetes: a gateway to precision medicine in diabetes.

Zhang H, Colclough K, Gloyn A, Pollin T J Clin Invest. 2021; 131(3).

PMID: 33529164 PMC: 7843214. DOI: 10.1172/JCI142244.


References
1.
Gloyn A, Pearson E, Antcliff J, Proks P, Bruining G, Slingerland A . Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004; 350(18):1838-49. DOI: 10.1056/NEJMoa032922. View

2.
Pedelini L, Garcia-Gimeno M, Marina A, Gomez-Zumaquero J, Rodriguez-Bada P, Lopez-Enriquez S . Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations. Protein Sci. 2005; 14(8):2080-6. PMC: 2279319. DOI: 10.1110/ps.051485205. View

3.
Naylor R, Greeley S, Bell G, Philipson L . Genetics and pathophysiology of neonatal diabetes mellitus. J Diabetes Investig. 2014; 2(3):158-69. PMC: 4014912. DOI: 10.1111/j.2040-1124.2011.00106.x. View

4.
Magnuson M . Glucokinase gene structure. Functional implications of molecular genetic studies. Diabetes. 1990; 39(5):523-7. DOI: 10.2337/diab.39.5.523. View

5.
Matschinsky F . GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?. Trends Pharmacol Sci. 2013; 34(2):90-9. DOI: 10.1016/j.tips.2012.11.007. View